Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.

CONCLUSIONS: As single-dose perioperative agents, both thiotepa and MMC were associated with similar recurrence-free survival rates.
PMID: 31629441 [PubMed - in process]

Source: Canadian Journal of Urology - October 21, 2019 Category: Urology & Nephrology Tags: Can J Urol Source Type: research